Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 20/20 | 0.83 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 0.83 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.83 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.83 |
| ▸ | NSD2 | O96028 | 1/20 | 0.83 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.83 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.83 |
| ▸ | BID | P55957 | 1/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.83 |
| ▸ | ASPH | Q12797 | 1/20 | 0.83 |
| ▸ | BAD | Q92934 | 1/20 | 0.83 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.83 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.83 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19503727 | 0.95 | BCL2 (0.75) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL21233544 | 0.95 | BCL2 (0.75) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL21573176 | 0.95 | BCL2 (0.83) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL18635202 | 0.95 | BCL2 (0.75) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL21573213 | 0.94 | BCL2 (0.83) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL20368840 | 0.94 | BCL2 (0.74) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL19504148 | 0.94 | BCL2 (0.74) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL23489377 | 0.93 | BCL2 (0.75) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL19939538 | 0.93 | BCL2 (0.74) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL21851473 | 0.92 | BCL2 (0.71) | BCL2BCL2L1MCL1BCL2L2NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4215197-A1 | INHIBITING MUTANT IDH-1 | Forma Therapeutics, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230066088-A1 | INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1) | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11576906-B2 | Inhibiting mutant IDH-1 | FORMA THERAPEUTICS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-3720442-B1 | INHIBITING MUTANT IDH-1 | FORMA THERAPEUTICS INC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11376246-B2 | Inhibiting mutant IDH-1 | FORMA THERAPEUTICS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11311527-B2 | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) | FORMA THERAPEUTICS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210196701-A1 | INHIBITING MUTANT IDH-1 | FORMA THERAPEUTICS, INC. | 2021-07-01 | — | — | US | disclosed |
| WO-2021080955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2020232381-A1 | INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1) | FORMA THERAPEUTICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| US-20200297717-A1 | INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1) | FORMA THERAPEUTICS, INC. | 2020-09-24 | — | — | US | disclosed |
| US-20200108060-A1 | INHIBITING MUTANT IDH-1 | FORMA THERAPEUTICS, INC. | 2020-04-09 | — | — | US | disclosed |
| WO-2020023435-A1 | VENETOCLAX BASIC SALTS AND PROCESSES FOR THE PURIFICATION OF VENETOCLAX | ALBANY MOLECULAR RESEARCH, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20190350919-A1 | INHIBITING MUTANT IDH-1 | FORMA THERAPEUTICS, INC. | 2019-11-21 | — | — | US | disclosed |
| WO-2019161221-A2 | SELECTIVE BCL-2 INHIBITORS IN COMBINATION WITH AN ANTI-PD-1 OR AN ANTI-PD-L1 ANTIBODY FOR THE TREATMENT OF CANCERS | ABBVIE INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| WO-2019150253-A1 | SOLID STATE FORMS OF VENETOCLAX AND ITS PROCESS FOR THE PREPARATION THERE OF | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2019-08-08 | — | — | WO | disclosed |
| WO-2018127130-A1 | COMPOUNDS AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018029711-A2 | PROCESS FOR THE PREPARATION OF VENETOCLAX | MYLAN LABORATORIES LIMITED (IN) | 2018-02-15 | — | — | WO | disclosed |
| EP-2643322-B1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2017-08-30 | — | — | EP | disclosed |
| WO-2017023584-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | GILEAD SCIENCES, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210196701-A1 | INHIBITING MUTANT IDH-1 | IDH3A, IDH3B, IDH1 | BCL2 701/4885BCL2L1 472/4885MCL1 10/4885 |
| US-20190350919-A1 | INHIBITING MUTANT IDH-1 | IDH3A, IDH3B, IDH1 | BCL2 701/4885BCL2L1 472/4885MCL1 10/4885 |
| US-11376246-B2 | Inhibiting mutant IDH-1 | IDH3A, IDH3B, IDH1 | BCL2 701/4885BCL2L1 472/4885MCL1 10/4885 |
| US-11311527-B2 | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) | IDH1, IDH3B, IDH2 | BCL2 1683/4885BCL2L1 770/4885MCL1 57/4885 |
| US-20230066088-A1 | INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1) | IDH1, IDH3B, IDH2 | BCL2 1683/4885BCL2L1 770/4885MCL1 57/4885 |
| US-11576906-B2 | Inhibiting mutant IDH-1 | IDH3A, IDH3B, IDH1 | BCL2 701/4885BCL2L1 472/4885MCL1 10/4885 |
| US-20200108060-A1 | INHIBITING MUTANT IDH-1 | IDH3A, IDH3B, IDH1 | BCL2 701/4885BCL2L1 472/4885MCL1 10/4885 |
| US-20200297717-A1 | INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1) | IDH1, IDH3B, IDH2 | BCL2 1683/4885BCL2L1 770/4885MCL1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.